| __timestamp | Blueprint Medicines Corporation | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 91733000 |
| Thursday, January 1, 2015 | 14456000 | 87644000 |
| Friday, January 1, 2016 | 19218000 | 92365000 |
| Sunday, January 1, 2017 | 27986000 | 85656000 |
| Monday, January 1, 2018 | 47928000 | 88196000 |
| Tuesday, January 1, 2019 | 96388000 | 89971000 |
| Wednesday, January 1, 2020 | 157743000 | 93413000 |
| Friday, January 1, 2021 | 195293000 | 91355000 |
| Saturday, January 1, 2022 | 237374000 | 113676000 |
| Sunday, January 1, 2023 | 295141000 | 198366000 |
| Monday, January 1, 2024 | 359272000 | 218935000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Blueprint Medicines Corporation and Taro Pharmaceutical Industries Ltd. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Blueprint Medicines Corporation's SG&A expenses surged by an impressive 3,640%, reflecting its aggressive growth and expansion strategies. In contrast, Taro Pharmaceutical Industries Ltd. maintained a more stable trajectory, with a modest increase of about 116% over the same period. This divergence highlights Blueprint's focus on scaling operations, while Taro appears to prioritize steady, controlled growth.
Interestingly, the data for 2024 shows a gap for Blueprint, suggesting a potential shift or reevaluation in their financial strategy. As these companies continue to evolve, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.